Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie announced the successful topline results from the Phase 2 SLEek trial of upadacitinib (RINVOQ), achieving the primary endpoint in patients with systemic lupus erythematosus (SLE). The trial met the SLE Responder Index (SRI-4) criteria with a steroid dosage of ≤10 mg prednisone equivalent after 24 weeks. The study included 341 participants across five treatment groups, and no new safety concerns were reported. AbbVie plans to advance upadacitinib into Phase 3 trials, highlighting its commitment to addressing unmet needs in SLE treatment.
AbbVie announced positive results from the Phase 3 INSPIRE study for risankizumab (SKYRIZI), an IL-23 inhibitor for ulcerative colitis. At week 12, 20.3% of patients on risankizumab achieved clinical remission, compared to 6.2% on placebo (p0.00001). All secondary endpoints, including endoscopic and histologic improvements, were met, with significant differences noted: 36.5% of risankizumab patients showed endoscopic improvement versus 12.1% for placebo. The safety profile was consistent with previous studies, with no new safety risks identified. The maintenance study for ulcerative colitis is ongoing, and the drug is currently not FDA-approved for this indication.
AbbVie (NYSE: ABBV) announced on March 22, 2023, that it received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for ABBV-951 (foscarbidopa/foslevodopa) aimed at treating motor fluctuations in adults with advanced Parkinson's disease. The FDA's letter requests additional information about the delivery device but does not require further efficacy or safety trials for the drug. AbbVie plans to resubmit the NDA promptly. The application was based on a successful Phase 3 clinical trial showing significant improvement in patient outcomes compared to existing oral treatments.
AbbVie announced positive results from a phase 3b study of SKYRIZI (risankizumab) for treating plaque psoriasis in patients with a prior suboptimal response to IL-17A inhibitors. At week 16, 56.3% of patients achieved significant symptom reduction, with 63.0% reaching clear or almost clear skin by week 52. Additionally, 26.2% reported complete skin clearance at week 52. No new safety concerns emerged during the study. This reinforces SKYRIZI's role for difficult-to-treat psoriasis, supporting ongoing research commitments from AbbVie.
AbbVie announced the launch of a new documentary titled "Under My Skin: Untold Stories of Life with Eczema," which debuted at SXSW 2023 in Austin, Texas. The film aims to highlight the physical and emotional struggles of individuals living with eczema, a chronic skin disease affecting over 31 million Americans. Directed by Redglass Pictures, the documentary presents real-life stories to inspire viewers to seek help. It will be available for U.S. audiences to stream on The Roku Channel starting April 1, 2023. The initiative reflects AbbVie’s commitment to supporting the eczema community and raising awareness about the disease's deeper impacts.
AbbVie (NYSE: ABBV) will present over 20 abstracts at the 2023 American Academy of Dermatology Annual Meeting from March 17-21 in New Orleans. The highlights include a late-breaking presentation on the long-term efficacy and safety of risankizumab in moderate to severe plaque psoriasis, with over 256 weeks of follow-up data. AbbVie emphasizes its commitment to improving outcomes for patients with immune-mediated skin conditions, showcasing research on psoriatic disease, atopic dermatitis, and hidradenitis suppurativa. These presentations reflect AbbVie's strong investment in its dermatology portfolio.
On March 8, 2023, Allergan Aesthetics, part of AbbVie (NYSE: ABBV), announced a partnership with IFundWomen to support women entrepreneurs on International Women's Day. The initiative provides 20 grants of $25,000 each along with a year of coaching and mentorship to help close the 'Confidence Gap' in business. Women entrepreneurs face significant funding disparities, receiving only about 2% of venture capital, impacting their growth potential. Applications are open until April 7, 2023, with recipients announced in June 2023. The program aims to empower future women leaders by providing essential resources for success.
AbbVie (NYSE: ABBV) will present at the Barclays Global Healthcare Conference on March 15, 2023, at 12:35 p.m. Central time. Key executives including Robert A. Michael and Scott Reents will be featured in the presentation. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later the same day. AbbVie is focused on innovative therapies across multiple therapeutic areas, such as immunology and oncology. For more details, visit www.abbvie.com.
AbbVie (NYSE: ABBV) will present at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 8:10 a.m. Central time. Key executives, including Robert A. Michael, Scott Reents, Jeffrey R. Stewart, and Roopal Thakkar, will participate in the event. Investors can access a live audio webcast on AbbVie's Investor Relations website, with an archived version available later that day.
AbbVie aims to develop innovative medicines across various therapeutic areas, including immunology, oncology, neuroscience, and others. For more information, visit www.abbvie.com.
AbbVie will showcase 24 abstracts related to inflammatory bowel diseases (IBD) at the 18th ECCO Congress from March 1-4, 2023, in Copenhagen, Denmark. This includes six oral presentations focusing on SKYRIZI® (risankizumab) for Crohn's disease and RINVOQ® (upadacitinib) for ulcerative colitis. Notable presentations will cover efficacy outcomes and clinical responses from multiple studies, including ADVANCE, MOTIVATE, and FORTIFY. AbbVie emphasizes its commitment to advancing treatment options for IBD patients, with crucial analyses set to impact standards of care.